Sutro Biopharma (STRO) Total Current Liabilities (2017 - 2025)

Sutro Biopharma's Total Current Liabilities history runs 9 years deep, the most recent figure standing at $75.1 million for Q4 2025.

• In Q4 2025, Total Current Liabilities fell 43.03% year-over-year to $75.1 million; the TTM figure through Dec 2025 stood at $75.1 million (down 43.03% YoY), while the FY2025 annual figure was $75.1 million, down 43.03% from the prior year.
• Total Current Liabilities came in at $75.1 million for Q4 2025 at Sutro Biopharma, up from $71.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $133.0 million in Q1 2025 to a low of $22.7 million in Q1 2021.
• A 5-year average of $72.8 million and a median of $69.5 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 93.65% in 2024 and slumped 45.24% in 2025, its largest moves.
• Sutro Biopharma's Total Current Liabilities stood at $41.7 million in 2021, then soared by 59.45% to $66.5 million in 2022, then jumped by 40.87% to $93.7 million in 2023, then surged by 40.69% to $131.9 million in 2024, then sank by 43.03% to $75.1 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $75.1 million, $71.9 million, and $74.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison